Published online before print May 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York
2Correspondence: Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021. E-mail: xim2002{at}med.cornell.edu
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. This study contributes to the elucidation of the molecular mechanisms underlying the interaction between a progressive malignancy and the immune defense apparatus.
Key Words: activated protein-1 • cytotoxic T lymphocyte • natural killer cells • macrophage • tumor immunity
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Tumors, however, often evade immune activation by producing immunosuppressive agents such as IL-10 and transforming growth factor-ß (TGF-ß), which seriously dampen immune activation [12 ]. Indeed, dysregulation of IL-12 occurs between mouse mammary tumor-proximal [13 , 14 ] and distal [15 ] immune cell populations.
Prostaglandins (PGs) are multipotential mediators in many biological responses. Numerous studies have demonstrated that PGs are important regulators of macrophages [16 17 18 19 20 ]. PGs produced by tumor cells or tumor-associated host cells (macrophages, endothelial cells, and stromal cells) have long been considered to play a stimulating role in the progression and metastasis of a variety of animal and human tumors [21 22 23 24 ]. The production and release of PGE2 by tumors, in particular, have been associated with general suppression of immune responses. It has also been demonstrated directly in a variety of systems to be a potent inhibitor of IL-12 production by macrophages and DC [13 , 25 26 27 28 29 30 31 32 ]. PGE2 signal transduction is mediated through seven transmembrane prostanoid receptors, primarily EP2 and EP4. It involves G proteins coupled to these receptors and leads to induction of intracellular cyclic adenosine monophosphate (cAMP) accumulation [33 , 34 ]. The inhibitory effects of PGE2 on IL-12 production are a result of its cAMP-inducing activity, as they could be mimicked by other cAMP inducers and are independent of IL-10, as neutralizing anti-IL-10 antibodies are unable to reverse this inhibition [25 ].
TS/A is an aggressive and poorly immunogenic cell line established from a moderately differentiated mammary adenocarcinoma that arose spontaneously in a multiparous BALB/c mouse [35 ]. It grows progressively, kills nu/nu and syngeneic mice, and gives rise to lung metastases. It expresses major histocompatibility complex class I (H-2Dd, H-2Kd) but not class II molecules, secretes granulocyte-colony stimulating factor (CSF), granulocyte macrophage-CSF, TGF-ß, basic fibroblast growth factor, and vascular endothelial growth factor, and does not stimulate a syngeneic antitumor response in vivo nor in mixed lymphocyte-tumor cell cultures [36 ]. IL-12 administered to TS/A tumor-bearing mice via various routes at different stages of tumor establishment has been shown to cause the rejection of the tumor in wild-type BALB/c mice through a CD8+ T-lymphocyte-dependent reaction associated with macrophage infiltration, vessel damage, and necrosis. A certain degree of tumor immune memory is also established following IL-12 treatment [37 , 38 ].
4T1 is a tumor cell line isolated from a single, spontaneously arising mammary tumor from a BALB/BfC3H mouse (mouse mammary tumor virus+; [39 ]). The 4T1 tumor closely mimics human breast cancer in its anatomical site, immunogenicity, growth characteristics, and metastatic properties [40 ]. From the mammary gland, 4T1 tumor spontaneously metastasizes to a variety of target organs including the lung, bone, brain, and liver through primarily a hematogenous route [41 ]. IL-12 administration to 4T1 tumor-bearing mice causes a substantial reduction in spontaneous metastases in the lungs and significantly prolongs their survival time [42 ].
These properties make TS/A and 4T1 mammary tumor models excellent systems in which to investigate the cellular and molecular mechanisms involved in IL-12 production and IL-12-mediated control of the malignant development. In the present study, we asked two fundamental questions: How does tumor-derived PGE2 inhibit IL-12 production by macrophages? What are the effects of reversing the inhibition of IL-12 expression in mice bearing these mammary tumors?
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Reagents
All antibodies used for supershift were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). PGE2 and NS-398 were purchased from Caymen Chemicals (Ann Arbor, MI).
Plasmids
Dr. Stephen Smale (University of California, Los Angeles) provided the mouse IL-12 p40 reporter construct spanning between –356 and +56 [43
]. We [44
] generated the human tumor necrosis factor 
(TNF-) promoter construct. Dr. Thomas Curren (St. Jude Children’s Hospital, Memphis, TN) and A-Fos, by Dr. Charles Vinson (National Cancer Institute, Bethesda, MD) provided expression vectors for c-Fos and c-Jun. All plasmids were prepared using the endotoxin-free maxi kit from Qiagen (Valencia, CA).
Tumor implantation, size measurement, lung metastasis assay
TS/A mammary carcinoma cells (1x105) were injected subcutaneously (s.c.) into the flank of recipient mice. 4T1 tumor cells (1x105) were injected s.c. into the abdominal mammary gland area of mice in 0.1 ml of a single-cell suspension in phosphate-buffered saline on Day 0. The dose of tumor implantation was empirically determined to give rise to tumors of 
10 mm in diameter in untreated wild-type mice in 21–23 days. Primary tumors were measured using electronic calipers every 2–3 days. Tumor size was the square root of the product of two perpendicular diameters. Numbers of metastatic 4T1 cells in lung were determined by the clonogenic assay [40
].
IL-12 and NS-398 treatment
Recombinant murine (rm)IL-12 was provided by Genetics Institute (Cambridge, MA). IL-12 treatment was given by intraperitoneal (i.p.) injection at 500 ng (TS/A) four times a week in consecutive days with a 3-day rest or 1 µg (4T1) per mouse every other day, starting on Day 7 until the end of each experiment, unless otherwise described. This regiment of IL-12 was well tolerated with no signs of overt toxicity. NS-398 was given i.p. at 10 mg/kg five times a week in five consecutive days with a 2-day rest. This dosing and scheduling were adapted from a similar study by Stolina et al. [30
].
Cells
The murine macrophage cell line RAW 264.7 was obtained from American Type Culture Collection (Manassas, VA). Inflammatory peritoneal exudate macrophages were obtained by lavage 3 days after injection of sterile, 3% thioglycolate broth (2 ml i.p.). Cells were washed and resuspended in RPMI containing 10% fetal calf serum (FCS) and standard supplements. Macrophages were plated in 48-well tissue-culture dishes (0.5x106 cells/well). After 2 h incubation to allow for adherence of macrophages, monolayers were washed three times to remove nonadherent cells and were incubated with RPMI-1640 medium containing 10% FCS and standard supplements. For stimulation, cells were treated the next day with lipopolysaccharide (LPS; 1 µg/ml), or murine interferon- (mIFN-; 10 ng/ml), first for 16 h (priming), followed by LPS.
Enzyme-linked immunosorbent assays (ELISA)
Supernatants from cultured cells were harvested 24 h after appropriate stimulation. mIL-12 p40, p70, and IL-10 were detected by ELISA (BD PharMingen, San Diego, CA) according to the manufacturer’s instructions. PGE2 was assayed by an enzyme immunoassay kit from Cayman Chemicals. Mouse TGF-ß1 was measured by ELISA with a rat anti-mouse monoclonal capture antibody (A75-2.1) from BD PharMingen.
RNase protection assay (RPA)
Mouse macrophages were pretreated with or without IFN- for 16 h followed by treatment with LPS for an additional 4 h. Total RNA (10 µg) of each sample was subjected to analysis by the multiprobe RNase protection kit mCK2b (BD PharMingen) according to the manufacturer’s instructions.
Transient transfection
Transient transfections were performed by electroporation as described previously [45
]. For cotransfections with effector expression vectors, the total amount of expression vectors was kept constant. Each cotransfection was done with a constant amount of a mixture of the effector vector (c-Fos or c-Jun) and control vector [cytomegalovirus (CMV)500]. The only variation is the ratio of the effector vector and control vector in the mix in each transfection. Transfection efficiency was routinely monitored by ß-galactosidase (ß-gal) assay by cotransfection with 3 µg pCMV-ß-gal plasmid. Variability in ß-gal activity between samples was typically within 5%. Lysates were used for luciferase and ß-gal assays.
Nuclear extract preparation
Nuclear extracts were prepared according to the method of Schreiber et al. [46
].
Electrophoretic mobility shift assay (EMSA)
EMSA and supershift were performed as described previously [47
]. The activated protein-1 (AP-1) oligonucleotide used was CGCTTGATGACTCAGCCGGGA; the underlined sequence denotes the consensus-binding site.
Statistical tests
Tumor growth and metastasis data to be compared were first subjected to normality test (Kolmogorov-Smirnov test). When the samples studied were normally distributed, statistical comparisons were performed using the Student’s t-test. Where the samples deviated from normality, a nonparametric, Mann-Whitney Rank-Sum test was used for comparisons. Statistical analyses were performed using SigmaStat software. For all experiments, the mean and SD or SEM are depicted.
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
 View larger version (20K): [in a new window] |
Figure 1. Effects of IL-12 on TS/A and 4T1 tumor growth and metastasis in syngeneic mice. TS/A (a) and 4T1 (b) mammary carcinoma cells were injected s.c. in the abdominal mammary gland. Tumor growth was monitored every 2–3 days, and tumor size in diameter (mm) was measured with an electronic caliper. Each data point is comprised of five mice (TS/A) and 10 mice (4T1), respectively. Error bars represent standard deviation. IL-12 treatment started on Day 7 and was injected i.p. four times a week at 500 ng (a) or 1 µg (b) per mouse. The differences in tumor size between control and IL-12-treated groups on Day 23 are highly significant, based on Student’s t-test. Data shown represent at least three independent experiments with similar results.
|
and LPS [45
]. TS/A and 4T1 but not RAW264.7 cells produced large amounts of PGE2 (Fig. 2a
) but no detectable levels of IL-10 (data not shown). Moreover, PGE2 production by the mammary tumor cells could be effectively blocked by the COX-2-specific inhibitor NS-398 (Fig. 2a)
, suggesting that COX-2 is responsible for the synthesis of a majority of PGE2 in TS/A and 4T1 cells. All cell lines also produced significant amounts of TGF-ß1, which was not affected by the NS-398 treatment (Fig. 2b)
.
 View larger version (17K): [in a new window] |
Figure 2. PGE2 and TGF-ß1 production by tumor cell lines. Murine mammary adenocarcinoma cell lines TS/A and 4T1 and myeloid leukemia cell line RAW264.7, all of BALB/c origins, were cultured, and supernatant was assayed by ELISA for production of PGE2 (a) and TGF-ß1 (b) in the presence or absence of 2 x 10–5 M NS-398. Data are representative of three separate experiments. The effective concentration of NS-398 used was determined by titrations. Production of active TGF-ß1 was measured by heating at 80°C for 10 min.
|
and LPS (to produce IL-12). Figure 3a
shows that the tumor cell media (TCM) of 4T1 cells was able to suppress IL-12 p70 production by macrophages dose-dependently, and 6% of transferred TCM was able to inhibit IL-12 production completely. The IC50 was approximately 1.5% of TCM, which translated into 1.4 nM based on the amount of PGE2 produced by 4T1 cells (Fig. 2a)
. The soluble factor(s) was not likely IL-10, as this cytokine was not measurable in the supernatant of 4T1 cells (data not shown). An experiment was designed to test if tumor cell-derived PGE2 was responsible for the observed inhibition of IL-12 production (Fig. 3b)
. Inhibition of PGE2 production by NS-398 treatment of the tumor cells completely restored IL-12 production inhibited by 4T1 cell culture-derived supernatant (Fig. 3c
, NS-398+TCM). Moreover, the addition of exogenous PGE2 to unconditioned medium (NS-398+NM+PGE2) was able to mimic the effect of TCM in an NS-398-resistant manner. These results strongly suggest that PGE2 is an essential factor for the IL-12-inhibiting activity present in the tumor cell-culture supernatant.
 View larger version (25K): [in a new window] |
Figure 3. PGE2 produced by 4T1 tumor cells inhibits IL-12 production by macrophages. (a) Murine peritoneal macrophages (M ) elicited by thioglycolate injection were cultured in normal media (NM) or increasing amounts (v:v) of TCM transferred from 4T1 cell cultures. Cells were immediately stimulated with IFN- (10 ng/ml) for 16 h, followed by LPS (1 µg/ml) stimulation for 24 h. IL-12 p70 was assayed by ELISA. (b) Flowchart of the experimental design to test if PGE2 secreted by 4T1 tumor cells was responsible for inhibition of IL-12. (c) Peritoneal macrophages were cultured in the presence of NM or mixed with 3% TCM with or without NS-398 (2x10–5 M) treatment followed by stimulation with IFN- and LPS. Note that in the third bar from the top, NS-398 was added to the 4T1 cell culture, not to the macrophage culture. Data are representative of two independent experiments. PGE2 was dissolved in ethanol and added to a final concentration of 10–6 M in 1:1000 dilution (0.1% ethanol final). Control cultures received ethanol.
|
80% suppression at 10–5M without toxicity to the cells. The IC50 was 50 nM. This estimated IC50 is considerably higher than that shown in Figure 3a
(1.4 nM). The reason for this discrepancy is not clear but may be attributable to the use of different batches of PGE2 in separate experiments.
 View larger version (56K): [in a new window] |
Figure 4. Dose and kinetics of PGE2-mediated inhibition of macrophage IL-12 production. (a) Dose dependency of PGE2. Thioglycolate-elicited murine macrophages were primed with IFN- (10 ng/ml) for 16 h, followed by LPS (1 µg/ml) stimulation for 24 h. PGE2 was added at various concentrations as indicated. The production of IL-12 p70 was measured by ELISA, and the values were normalized to that of control (without PGE2) as percentages. (b) Kinetics of PGE2. PGE2 was added at 10–6 M to macrophage cultures stimulated as described (a) at different times. The time-points indicate the number of hours before LPS stimulation. ELISA was performed to measure IL-12 p40 (b) and p70 (c) production in culture supernatant. (d) RPA. Total RNA was isolated from peritoneal macrophages stimulated with LPS or IFN- plus LPS in vitro, together with PGE2 (10–6M), added at the same time as LPS. RPA was performed as described in Materials and Methods. Lanes 1–3, No PGE2; lanes 4–6, PGE2-treated. All results shown here are representative of two to three independent experiments with similar outcomes. *, Bands of incompletely digested probes.
|
To evaluate the role of PGE2 in transcriptional regulation of IL-12 p40 and p35 genes at the mRNA level, we analyzed the steady-state mRNA expression of several cytokines produced by activated macrophages by a multiprobe RNase protection assay (Fig. 4d)
. LPS moderately, IFN-, and LPS strongly stimulated the mRNA expression of IL-12 p35 and p40 in peritoneal macrophages (lanes 2 and 3). Expression of IL-12 p35 and p40 mRNAs was inhibited by PGE2 treatment of LPS- and IFN-/LPS-activated macrophages (lanes 5 and 6). Expression of several other proinflammatory cytokine mRNAs was not significantly inhibited by PGE2: IL-1, IL-1ß, IL-18, and IL-6. These results are consistent with the general anti-inflammatory role of PGE2 in macrophages. We also examined the stability of IL-12 p35 and p40 mRNA following PGE2 treatment in the presence of actinomycin D and found no evidence of a role of PGE2 in the regulation of the decaying of these mRNAs (data not shown).
PGE2 inhibits IL-12 p40 at the level of transcription
To determine if the inhibitory effects of PGE2 on IL-12 protein and mRNA expression were transcriptional, we performed luciferase reporter assays to measure the mouse IL-12 p40 promoter activity in RAW264.7 cells following treatment with PGE2. The RAW264.7 cell line has been used widely by us and others for the investigation of macrophage-derived cytokine gene expression because of its easiness to transfect and its similarity to primary macrophages [45
, 47
, 48
], in contrast to the difficulties in the transfection of primary macrophages. Figure 5a
shows that the IL-12 p40 promoter-driven luciferase activity was induced by LPS, 32-fold compared with the unstimulated control (medium), which was further enhanced by IFN- priming, to 70-fold. The stimulation of the IL-12 p40 promoter by LPS or IFN- plus LPS was reduced strongly by PGE2 treatment. Similarly, LPS (eightfold) potently stimulated the promoter activity of TNF- alone or by IFN- plus LPS (28-fold), and PGE2 treatment significantly reduced the magnitude of stimulation by these agents (Fig. 5b)
. These results demonstrate that PGE2 can exert its repressive effects on the expression of proinflammatory cytokines at the transcriptional level.
 View larger version (26K): [in a new window] |
Figure 5. Transcriptional regulation of inflammatory cytokines by PGE2. The mouse IL-12 p40 promoter and human TNF- promoter linked to the firefly luciferase reporter gene were transiently transfected into RAW264.7 cells by electroporation. Cells were then stimulated with IFN- (16 h) in the presence or absence of PGE2 (10–5M) or an equal volume of ethanol (solvent) followed by LPS treatment (7 h). Cells were harvested, and lysates were prepared and used for luciferase assay. Relative luciferase activity is calculated as fold of induction comparing LPS or IFN-/LPS-stimulated promoter activity with that of unstimulated luciferase activity (medium), which is set as 1. (a) IL-12 p40 and (b) TNF-. Data shown are combined from two independent experiments with SEM.
|
and IL-4 have been attributed at least in part to the down-regulation of c-Fos by these two cytokines during the priming phase [53
, 54
].
To confirm the inhibitory effects of AP-1 on the IL-12 p40 gene expression, we used a dominant-negative mutant of AP-1, A-Fos, which was designed to contain an acidic, amphipathic protein sequence appended onto the N terminus of the Fos leucine zipper, replacing the normal basic region critical for DNA binding. The acidic extension and the Jun basic region form a heterodimeric coiled-coil structure that stabilizes the complex over 3000-fold and prevents the basic region of Jun from binding to DNA [55
]. We measured the response of the endogenous IL-12 p40 gene by ELISA following transfection of the effector construct A-Fos (Fig. 6a A
) or its empty vector control, CMV500 (Fig. 6a C)
into RAW264.7 cells. IL-12 p40 secretion after LPS stimulation was dramatically enhanced by A-Fos expression without a visible impact on IL-12 p40 production stimulated with IFN- and LPS (Fig. 6a)
. We also examined the effects of A-Fos on the transcriptional response of the heterologous IL-12 p40 promoter reporter. Similarly, A-Fos greatly enhanced the response of the IL-12 p40 promoter to LPS stimulation without an impact on the IFN-/LPS-stimulated promoter activity (Fig. 6b)
. These results are consistent with the in vivo data showing that genetic deficiency of c-Fos renders macrophages more potent producers of IL-12 in response to LPS but not to IFN- plus LPS [53
].
 View larger version (38K): [in a new window] |
Figure 6. PGE2-induced and AP-1-mediated inhibition of IL-12 p40 gene expression. (a) Endogenous IL-12 p40 protein production is induced by A-Fos. Transient transfection into RAW264.7 cells was performed with the control vector CMV500 (C) or A-Fos (A). Supernatants were collected after LPS or IFN- plus LPS stimulation of the transfected cells. ELISA was performed to measure mIL-12 p40 secretion. Unstimulated cells produced no detectable levels of mIL-12 p40. The detection limit was 10 pg/ml. (b) A-Fos enhances IL-12 p40 transcription. Human IL-12 p40 promoter containing a 3.3-kb genomic sequence driving the firefly luciferase cDNA was transiently transfected into RAW264.7 cells by electroporation together with A-Fos (A) or its control vector CMV500 (C). Cells were stimulated with LPS or primed with IFN- for 15 h followed by LPS for 7 h. Cells were harvested, and lysates were prepared. Luciferase activity was measured. A summary of five separate experiments is shown with standard deviation. (c) A-Fos blocks the inhibition of IL-12 p40 production by PGE2 in RAW264.7 cells. Transient transfection into RAW264.7 cells was performed with an expression vector for A-Fos in the presence or absence of PGE2 (10–6M). Supernatants were collected for ELISA after IFN- plus LPS stimulation of the transfected cells. The transfection efficiency was approximately 20%, evaluated by ß-gal staining. The results shown here are a summary of two experiments with duplicate wells in each. (d) c-Fos and c-Jun inhibit IL-12 p40 transcription in RAW264.7 cells. Transient transfection in RAW264.7 cells was performed as in Figure 5
. The IL-12 p40 promoter-luciferase reporter was cotransfected with c-Fos, c-Jun, or a combination with c-Fos and c-Jun at different ratios of effector:reporter, starting at 0 (no effector) and ending at a ratio of 0.5:1 with a constant amount of reporter. Luciferase activity was measured from cell lysates after stimulation with IFN- (16 h) and LPS (7 h). The control vector for c-Fos and c-Jun, CMV500, was used with the IL-12 p40 promoter, where no effector was used. Data are representative of three independent experiments.
|
and LPS in the presence of PGE2. Figure 6c shows that PGE2 significantly inhibited IFN-/LPS-induced mIL-12 p40 production in this cell line. A-Fos expression in PGE2-treated RAW264.7 cells resulted in a completed reversal of its inhibitory effect, indicating that AP-1 is a critical mediator of the IL-12 p40-suppressing activity of PGE2. Finally, we directly assessed the effects of AP-1 on transcriptional activity of the IL-12 p40 promoter by transiently cotransfecting the p40 reporter construct with a vector expressing c-Fos or c-Jun. As shown in Figure 6d , c-Fos expression inhibited IL-12 p40 transcription in a dose-dependent manner on a molar basis, and c-Jun did so only at the highest concentration in this experiment. Coexpression of c-Fos and c-Jun resulted in an additive inhibition of p40 transcription, demonstrating a suppressive role of AP-1 in IL-12 p40 gene expression.
Inhibition of PGE2 production in vivo enhances control of tumor progression and IL-12/IFN- production
We hypothesized that as NS-398, a pharmacological inhibitor of COX-2 activity and PGE2 synthesis, is able to restore IL-12 production in vitro in macrophages, it may also be able to do so in vivo, leading to enhancement of tumor regression and/or reduction in metastasis in analogy to the effects of IL-12 administration in mammary tumor models.
To test this hypothesis, we treated 4T1 tumor-bearing mice with NS-398, IL-12, or NS-398 and IL-12 and measured the tumor growth and lung metastasis. NS-398 treatment did not slow the growth of the 4T1 tumor significantly compared with IL-12 treatment (Fig. 7a ). The combined use of IL-12 and NS-398 had a generally similar effect to the use of IL-12 alone. NS-398 treatment did reduce metastatic 4T1 cells in the lung by an order of magnitude (Fig. 7b) , and IL-12 treatment completely blocked lung metastases.
 View larger version (23K): [in a new window] |
Figure 7. Inhibition of 4T1 tumor growth by IL-12. (a) 4T1 tumor cells (105) were injected s.c. in the abdominal mammary gland with 0.1 ml of a single-cell suspension containing the indicated number of cells. Tumor growth was monitored every 2–3 days. NS-398 or IL-12 was given (1 µg) i.p. on Day 7 when the tumor size was 5 mm in diameter and every other day after that until Day 21 when the mice were killed. Each group was comprised of five mice. (b) Lung metastasis was measured at the end of this experiment (Day 21) by the 6-thioguanine clonogenic assay [56
]. (c) Peritoneal macrophages taken from the mice-bearing 4T1 tumor, treated with or without NS-398 in vivo, were stimulated or not in vitro with IFN- and LPS (IFN-/LPS) for 24 h. ELISA was performed to measure IL-12 p40 production in cell-free supernatant. (d) Splenocytes from the four groups of mice (107 cells/ml) were harvested 21 days after tumor injection, cultured, and stimulated with or without Concanavalin A (ConA) for 24 h. IFN- production in the supernatant was measured by ELISA.
|
and LPS in vitro, was strongly enhanced by this treatment. To measure IFN- production in response to IL-12 and NS-398 treatments, we used splenocytes, as they contain T lymphocytes, which are the major source of IFN-. The IL-12 and NS-398 treatments resulted in greater IFN- production from the splenocytes isolated from tumor-bearing mice following ConA stimulation in vitro (Fig. 7d)
, although the splenocytes from IL-12-treated animals were able to produce large amounts of IFN- without further in vitro stimulation. Taken together, these results indicate that the NS-398 treatment partially restored the immune capacity of the host with respect to IL-12 and IFN- production and antimetastasis. |
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Xin and Sriram [66
] have previously shown that vasoactive intestinal peptide (VIP), a naturally occurring neuropeptide widely distributed in the nervous system and a ligand for G protein-coupled receptors, inhibits production of IL-12 and nitric oxide (NO) but not TNF- production in macrophages stimulated with LPS or superantigens. The inhibitory effect of VIP on IL-12 production is cAMP-mediated [66
]. Delgado and Ganea [67
] further demonstrated that VIP inhibits IL-12 p40 transcription by regulating nuclear factor (NF)-
B and Ets activation. Thus, it is possible that PGE2-induced inhibition of IL-12 p40 transcription may also target NF-B- and Ets-related factors. An additional and significant player that might be involved in PGE2-induced inhibition of IL-12 p40 transcription is the inducible cAMP early repressor (ICER), which belongs to the cAMP response element-binding protein (CREB) [68
] and cAMP response-element modulator [69
] family of the basic leucine zipper transcription factors and acts as a dominant-negative regulator of cAMP-responsive transcription [70
]. In the case of the IL-2 gene induction during T cell activation, the presence of ICER before T cell activation is purported to form a transcriptionally inactive complex with NF of activated T cells (NFAT) on the IL-2 promoter, which fails to recruit CREB-binding protein, resulting in transcriptional inhibition [71
]. The relevance of ICER to PGE2-induced transcriptional repression of the IL-12 p40 gene is supported by the observation that NFAT is involved in the mIL-12 p40 transcriptional activation with a member of the IFN regulatory factor family of transcription factors, IFN consensus sequence-binding protein [72
].
In the in vivo experimentation, it is noted that NS-398 treatment, although substantial in terms of its effect on metastasis compared with the control group [a tenfold reduction (Fig. 7b)
], did not display as potent anti-tumor activities as those elicited by the IL-12 treatment. Another group applied the same regimen to the Lewis lung carcinoma (3LL) model with remarkable efficacy [30
]. In this model, inhibition of COX-2 led to marked lymphocytic infiltration of the tumor and reduced tumor growth. Treatment of mice with anti-PGE2 monoclonal antibody replicated the growth reduction seen in tumor-bearing mice treated with COX-2 inhibitors. COX-2 inhibition was accompanied by a significant decrease in IL-10 and a concomitant restoration of IL-12 production by antigen-presenting cells [30
]. The discrepancy might be explained by the possibility of a quantitative difference with respect to how much endogenous IL-12 was induced by the NS-398 treatment compared with the exogenous administration of rIL-12 at 1 µg every other day and by the fact that NS-398 and IL-12 were given to the animals at the same time on Day 7. NS-398 may need longer time to deliver its effects than the direct application of IL-12, as NS-398 works by blocking COX-2 first, which leads to a decreased level of PGE2 synthesis and ultimately, some restoration of endogenous IL-12 production. Third, as shown in Figure 2b
, NS-398 treatment does not have any effect on the production of TGF-ß by mammary tumor cells, which could explain in part a possible lack of full restoration of the production of endogenous IL-12. Finally, the lack of equivalent efficacy of NS-398 treatment could be a result of an impairment of IL-12 receptor (IL-12R) expression in the immune cells (NK cells, T cells, macrophages, and DC) of tumor-bearing mice, which were not fully restored by NS-398 treatment but were better restored by exogenous IL-12 treatment. Exposure of committed Th2 cells to IL-12 has been shown to be able to restore their full IL-12 responsiveness by up-regulating IL-12R expression [73
]. Alternatively, the inability of NS-398 to fully mimic the effects of exogenous IL-12 may not be attributable to simple, quantitative differences in IL-12 abundance. The consistent, additive effects of NS-398 to those of exogenous IL-12 (Fig. 7a
and 7d)
could suggest IL-12-independent contributions of COX-2 inhibition. Elevated PGE2 production is a common feature of human malignancies. This has been attributed to increased COX-2 expression and activity [74
75
76
]. It has been shown that PGE2 suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats [77
]. One noticeable effect of NS-398 was the ability to stimulate IFN- production in the spleen of the treated mice (Fig. 7d)
, which correlated with the significant efficacy of NS-398 in the suppression of lung metastasis of the 4T1 tumor. IFN- has been shown in the 4T1 tumor model to be a critical factor for the inhibition of metastasis [56
, 78
], although the mechanism by which IFN- suppresses metastasis remains to be determined.
The role of TGF-ß in tumor growth and metastasis is also an important issue that should not be overlooked in our system, as 4T1 and TS/A tumor cells produce large amounts of TGF-ß (Fig. 2b)
. The effects of TGF-ß in the biology of epithelial cells are complex. TGF-ß is a potent inhibitor of epithelial cell proliferation [79
]. However, in established carcinomas, autocrine/paracrine TGF-ß interactions can enhance tumor cell viability, migration, and metastases [80
]. Treatment of 4T1 tumor-bearing animals with IFN- or antisense TGF-ß gene-modified tumor cell vaccines reduced the number of clonogenic metastases to the lungs and liver [56
]. The lesser effects of NS-398 compared with IL-12 could be accounted for, at least in part, by the presence of TGF-ß. In this context, it is interesting to note that peritoneal macrophages from IL-12p40 gene knockout mice have a bias toward the M2 profile, spontaneously secreting large amounts of TGF-ß1 and responding to rIFN- with weak NO production, suggesting that IL-12 is a natural inhibitor of TGF-ß synthesis and/or activity.
The apparent discrepancy between our data, showing that systemic administration of rIL-12 could inhibit primary 4T1 tumor growth (Fig. 1)
, and that of Rakhmilevich et al. [42
], showing an inability of tumor-derived rIL-12 to suppress intradermal 4T1 tumor growth, could be reconciled by the observation of Cavallo et al. [81
], who compared the effects of local and systemic rIL-12 application in mice harboring the TS/A tumor. Whereas the immune events elicited via the two routes of rIL-12 administration seem to be the same, systemic rIL-12 is markedly more effective because of its ability to promptly elicit an antitumor response that is dependent on the cooperation of several key factors: indirect inhibition of angiogenesis by secondary cytokines (mainly IFN-) and third-level chemokines (inducible protein 10 and monokine induced by IFN-); systemic activation of leukocyte subsets capable of producing proinflammatory cytokines, CTL, and antitumor antibodies; and destruction of tumor vessels by polymorphonuclear cells [81
].
In summary, our study provides mechanistic evidence about the way tumor-derived PGE2 inhibits the expression of a crucial immune regulator, thus weakening the immune competence of the host. The information obtained from this study contributes to the overall effort to understand the host versus tumor interactions and to develop more effective strategies for cancer immunotherapy.
Received December 18, 2003; revised March 22, 2004; accepted April 13, 2004.
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
induction is associated with clinical response Clin. Cancer Res. 6,1678-1692 production in mammary tumor-bearing mice J. Immunol. 158,280-286[Abstract] B activation in tumor-associated macrophages J. Immunol. 164,762-767 gene expression by low doses of prostaglandin E2 and cyclic GMP Immunobiology 182,44-55[Medline] and IL-1 ß in murine peritoneal macrophages J. Immunol. 145,3333-3339[Abstract]B activation in J774 macrophages FEBS Lett. 440,76-80[CrossRef][Medline] (IFN-) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC) Clin. Exp. Immunol. 117,469-475[CrossRef][Medline] 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN--producing TS/A cells J. Immunol. 153,4604-4615[Abstract] receptor ligation J. Immunol. 166,4498-4506 in monocytic cells J. Exp. Med. 183,147-157 B7.1 and antisense TGF-ß gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma Cancer Immunol. Immunother. 50,229-240[CrossRef][Medline]B and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH) Mol. Hum. Reprod. 6,561-565 ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300 J. Biol. Chem. 276,12440-12448B and Ets activation J. Biol. Chem. 274,31930-31940 dependent J. Immunol. 169,5796-5804This article has been cited by other articles:
 |
|
 |
|
  G. Natarajan, S. Ramalingam, I. Ramachandran, R. May, L. Queimado, C. W. Houchen, and S. Anant CUGBP2 downregulation by prostaglandin E2 protects colon cancer cells from radiation-induced mitotic catastrophe Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1235 - G1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hu, J. Chen, L. Wang, and L. B. Ivashkiv Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation J. Leukoc. Biol., August 1, 2007; 82(2): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Franke, W. Lante, E. Kurig, L. G. Zoller, C. Weinhold, and A. Markewitz Is interferon gamma suppression after cardiac surgery caused by a decreased interleukin-12 synthesis? Ann. Thorac. Surg., July 1, 2006; 82(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Lewis and J. W. Pollard Distinct Role of Macrophages in Different Tumor Microenvironments Cancer Res., January 15, 2006; 66(2): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Shan, L. Chen, J. T. Njardarson, C. Gaul, X. Ma, S. J. Danishefsky, and X.-Y. Huang Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice PNAS, March 8, 2005; 102(10): 3772 - 3776. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
